pexidartinib + paclitaxel

Plexxikon MOA pexidartinib-paclitaxel

Targeted Indication Status Sites link to clinicaltrials.gov

Advanced Ovarian Cancer

Phase 2

Cleveland, OH
Columbus, OH
San Francisco, CA
Salt Lake City, UT
Rochester, MN
Denver, CO
Miami, FL
Birmingham, AL

NCT01525602

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Chambers SK. Future Oncology. 2009; 5(9); 1429-40. Denardo DG et al. Cancer Discovery. 2011; 1(1); 0F53-65.
Quail DF, Joyce JA. Nat Med. 2013; 19(11); 1423-37.